Loading…
Loading…
Bessemer Group Inc. boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 21,814.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,813 shares of the biopharmaceutical company's stock after buying an additional 52,572 shares during the quarter. Bessemer
WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, July 30, 2026, at 4:30 p.m.
The transaction generated $222,376 in gross proceeds, realized through the exercise of 2,464 options at $46.54 and their immediate sale at a weighted average price of $90.25. The disposition represented 4% of the insider's direct common stock holdings.
PTCT's rare disease portfolio expands as Sephience sales surge, while late-stage pipeline programs add new growth opportunities.
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for PTCT and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.